Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.
AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeuti...more >
|Materials for June 20, 2018 Annual Meeting|
|Latest News||more >|
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|